Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
*Only mismatch repair (MMR)-proficient (=MSS) advanced colorectal cancer.
*Antibody DS-8273a + Nivolumab (=agonistic TRAIL-R antibody DS-8273a + anti-PD-1)
*DS-8273a: decrease in myeloid-derived suppressive cells (MDSC)
*Columbia and Texas; some locations still not recruiting
*a phase I trial in Solid tumours and Lymphoma (Late stage disease) completed 2015 (NCT02076451)
December 2, 2016: Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody J. Bendell et al. https://drive.google.com/open?id=0Bwc5k ... 20xOHl1U2M